Metformin Sandoz

Metformin Hydrochloride, the active ingredient in Metformin Sandoz, is a biguanide presented as an oral dosage form for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to lower elevated blood glucose levels by improving the body’s response to insulin.

GNH USA supplies Metformin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution channels that meet EU quality standards and regulatory requirements. The product conforms to European Union pharmacopeial specifications.

Metformin Sandoz is an oral biguanide used to improve glycemic control in disorders of glucose metabolism.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Prediabetes (impaired glucose tolerance): delays progression to type 2 diabetes. - Polycystic ovary syndrome: reduces insulin resistance and may improve menstrual regularity.

Metformin Sandoz may cause a range of adverse reactions, most of which are related to the gastrointestinal tract or metabolic disturbances.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools. - Abdominal discomfort: cramps or pain. - Metallic taste: transient alteration of taste. - Loss of appetite: reduced desire to eat. - Weight loss: modest reduction in body weight.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal buildup of lactate. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic failure: signs of liver dysfunction. - Hypoglycemia: when combined with other glucose‑lowering agents. - Vitamin B12 deficiency: long‑term use may reduce B12 levels.

When prescribing Metformin Sandoz, clinicians should consider several safety factors to minimize risk.

- Renal function: avoid in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²). - Hepatic function: use cautiously in patients with liver disease. - Lactic acidosis risk: discontinue before surgeries or radiologic contrast studies. - Pregnancy and lactation: assess benefit‑risk as safety data are limited. - Drug monitoring: check renal function and blood glucose regularly. - Store at room temperature: keep in the original container, protect from moisture and heat.

Metformin Sandoz can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: increase risk of acute kidney injury and lactic acidosis. - Alcohol: may potentiate lactic acidosis. - Cimetidine: can raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor renal function and potassium. - Loop or thiazide diuretics: may affect renal clearance of metformin. - Other antidiabetic agents (e.g., sulfonylureas, insulin): increase risk of hypoglycemia. - Beta‑blockers: may mask hypoglycemia symptoms.